Current Neurobiology

Open access Commentary

Neuroinflammation as a Therapeutic Target in Alzheimer's and Parkinson's Disease

Evangeline Rose*

Department of Neurobiology, University of Oxford, United Kingdom

INTRODUCTION

Neurodegenerative diseases, including Alzheimer's Disease (AD) and Parkinson's Disease (PD), are characterized by progressive neuronal loss and associated cognitive and motor deficits. While the exact etiology of these diseases remains unclear, increasing evidence points to neuroinflammation as a significant contributing factor. Targeting neuroinflammation presents a promising therapeutic approach to mitigate the progression of these debilitating disorders. Neuroinflammation refers to the inflammatory response within the Central Nervous System (CNS) mediated by glial cells, particularly microglia and astrocytes. In healthy conditions, microglia serve as the primary immune cells of the brain, maintaining homeostasis and responding to injury. However, in neurodegenerative diseases, chronic activation of microglia leads to an overproduction of pro-inflammatory cytokines, reactive oxygen species and other inflammatory mediators, resulting in a toxic environment for neurons. This chronic neuro-inflammatory state is implicated in the pathogenesis of both AD and PD.

DESCRIPTION

In Alzheimer's disease, neuroinflammation is closely associated with the accumulation of amyloid-beta plaques and tau tangles. Activated microglia surround amyloid plaques, initially attempting to clear them. However, prolonged activation leads to a harmful inflammatory response that exacerbates neuronal damage. Studies have shown that the levels of inflammatory markers, such as interleukin-1β and tumor necrosis factor-alpha are elevated in the brains of AD patients. These cytokines can impair synaptic function, promote tau phosphorylation, and ultimately lead to neuronal death. Several therapeutic strategies aimed at reducing neuroinflammation in AD are under investigation. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, have been explored for their potential to reduce the risk of developing AD. However, clinical trials have yielded mixed results, prompting a search for more targeted therapies. Recent advancements in understanding the role of microglial activation have led to the exploration of small molecules that can modulate microglial activity. Additionally, therapies targeting specific inflammatory pathways, such as inhibitors of the NLRP3 inflammasome, are being studied for their potential to reduce neuroinflammation and improve cognitive function in AD patients. Similar to AD, neuroinflammation plays a crucial role in the pathogenesis of Parkinson's disease. In PD, the loss of dopaminergic neurons in the substantia nigra is accompanied by glial activation and the release of inflammatory mediators. Elevated levels of cytokines, such as IL-6 and TNF-α, have been detected in the cerebrospinal fluid of PD patients, indicating a chronic inflammatory state that contributes to neuronal degeneration.

CONCLUSION

Neuroinflammation represents a critical therapeutic target in the treatment of Alzheimer's and Parkinson's diseases. The chronic inflammatory responses observed in these conditions contribute to neuronal damage and disease progression. Understanding the underlying mechanisms of neuroinflammation has opened new avenues for therapeutic interventions, ranging from pharmacological agents to lifestyle modifications. As research continues to unveil the complex interplay between neuroinflammation and neurodegeneration, it is essential to prioritize the development of targeted therapies that can mitigate the effects of inflammation on neuronal health. By addressing neuroinflammation, we may pave the way for more effective treatment strategies, ultimately improving the quality of life for individuals affected by these devastating diseases.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

The author declares there is no conflict of interest in publishing this article.

Received:	02-September-2024	**Manuscript No:**	jcnb-24-21676
Editor assigned:	04-September-2024	**PreQC No:**	jcnb-24-21676 (PQ)
Reviewed:	18-September-2024	**QC No:**	jcnb-24-21676
Revised:	23-September-2024	**Manuscript No:**	jcnb-24-21676 (R)
Published:	30-September-2024	**DOI:**	10.21767/JCNB-24.3.26

Corresponding author Evangeline Rose, Department of Neurobiology, University of Oxford, United Kingdom, E-mail: evangeline@email.com

Citation Rose E (2024) Neuroinflammation as a Therapeutic Target in Alzheimer's and Parkinson's Disease. J Curr Neur Biol. 4:26.